Consensus statement: Anemia in HIV infection - Current trends, treatment options, and practice strategies

Clinical Therapeutics

Volumn 22, Issue 9, 2000, Pages 1004-1020

  Volberding, Paul ^a  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

Anemia; Antiretroviral therapy; Erythropoietin; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; CIDOFOVIR; CYCLOPHOSPHAMIDE; DIDANOSINE; DOXORUBICIN; ETOPOSIDE; GANCICLOVIR; HEMOGLOBIN; HYDROXYUREA; LAMIVUDINE PLUS ZIDOVUDINE; RECOMBINANT ERYTHROPOIETIN; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; BLOOD TRANSFUSION; CLINICAL FEATURE; CLINICAL TRIAL; CYTOMEGALIC INCLUSION BODY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG COST; DRUG FORMULATION; DRUG INDUCED DISEASE; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL DECISION MAKING; QUALITY OF LIFE; REVIEW; SURVIVAL RATE; TREATMENT PLANNING;

EID: 0033810233     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)80081-8     Document Type: Article

References (64)

1. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: Results from the multistate adult and adolescent spectrum of HIV disease surveillance project
2. Anemia and survival in HIV infection
3. Improved survival with correction of anemia in HIV disease
4. Hematologic complications of HIV infection
5. Fatigue in cancer and HIV/AIDS
6. Cytomegalovirus retinitis in advanced HIV-infected patients treated with protease inhibitors: Incidence and outcome over 2 years
7. Efficacy and tolerability of stavudine plus lamivudine in treatment-naive and treatment-experienced patients with HIV-1 infection
8. The use of hematopoietic growth factors in HIV infection and AIDS-related malignancies
9. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex
10. Serum immunoreactive erythropoietin in HIV-infected patients
11. Clinical uses of hematopoietic growth hormones in HIV-related illnesses
12. Management of the hematological complications of HIV infection
13. HIV-1 suppression of hematopoiesis in vitro mediated by envelope glycoprotein and TNF-α
14. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome
15. Parvovirus B19 infection in human immunodeficiency virus type 1-infected persons failing or intolerant to zidovudine therapy
16. Hydroxyurea in the treatment of HIV-1
17. In vivo and in vitro comparison of the short-term hematopoietic toxicity between hydroxyurea and trimidox or didox, novel ribonucleotide reductase inhibitors with potential anti-HIV-1 activity
18. Profound and unanticipated anemia with lamivudine-zidovudine combination therapy in zidovudine-experienced patients with HIV infection
19. Combination therapy of chronic hepatitis C with ribavirin and interferon - The European experience
20. Psychometric validation of the revised Functional Assessment of Human Immunodeficiency Virus Infection (FAHI) quality of life instrument
21. Anemia, fatigue, and quality of life in people with cancer and HIV infection
22. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: Results of a tripart assessment survey
23. Infection with the human immunodeficiency virus: Clinical manifestations and their relationship to immune deficiency. A report from the Multicenter AIDS Cohort Study
24. Efficacy of zidovudine treatment in homosexual men with AIDS-related complex: Factors influencing development of AIDS, survival and drug intolerance
25. Predictors of outcome in AIDS patients receiving zidovudine
26. Survival experience among patients with AIDS receiving zidovudine
27. Racial and ethnic differences in outcome in zidovudine-treated patients with advanced HIV disease
28. Factors influencing outcome of treatment with zidovudine of patients with AIDS in Australia
29. Zidovudine therapy in an inner city population
30. Natural history of HIV-1 infection and predictors of survival in a cohort of HIV-1 seropositive injecting drug users
31. Early predictors of survival in symptomatic HIV-infected persons treated with high-dose zidovudine
32. Factors influencing survival after AIDS: Report from the Multicenter AIDS Cohort Study (MACS)
33. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe
34. Multivariate models for predicting progression to AIDS and survival in human immunodeficiency virus-infected patients
35. + lymphocyte response to zidovudine as a predictor of AIDS-free time and survival time
36. Multicohort analysis project workshop. Part I. Immunologic markers of AIDS progression: Consistency across five HIV-infected cohorts
37. 6/l
38. Dementia in AIDS patients: Incidence and risk factors
39. Antiretroviral therapy in adults: Updated recommendations of the international AIDS society - USA panel
40. Transfusion practices in human immunodeficiency virus-infected patients
41. Transfusion-induced immunomodulation and its clinical consequences
42. Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy
43. Clinical implications of human T-cell leukemia virus type-I/II associated diseases
44. Iron overload in multiply transfused patients who are HIV seropositive
45. Allogeneic leukocytes but not therapeutic blood elements induce reactivation and dissemination of latent human immunodeficiency virus type 1 infection: Implications for transfusion support of infected patients
46. Transfusion of blood components to persons infected with human immunodeficiency virus type 1: Relationship to opportunistic infection
47. Early transfusion and the length of survival in acquired immunodeficiency syndrome: Experience with a population receiving medical care at a public hospital
48. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice
49. Recombinant human erythropoietin in the treatment of the anaemia of cancer
50. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: Results of double-blind and open-label follow-up studies
51. Recombinant human erythropoietin for treatment of anemia in persons with AIDS not receiving zidovudine
52. Recombinant human erythropoietin for patients with AIDS treated with zidovudine
53. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials
54. Recombinant human erythropoietin treatment: Investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Overall results
55. Recombinant human erythropoietin and health-related quality of life of AIDS patients with anemia
56. Epoetin alfa therapy for anaemia in HIV-infected patients: Impact on quality of life
57. Red cell autoantibodies in patients with acquired immune deficiency syndrome
58. Practice strategies for elective red blood cell transfusion
59. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects
60. A safety and efficacy comparison study of two dosing regimens of epoetin alfa in patients undergoing major orthopedic surgery
61. Cost-effectiveness of recombinant human erythropoietin versus transfusion in the treatment of zidovudine-related anemia in HIV-infected children
62. Cost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease
63. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study